Imperial College London

Professor Pernilla Lagergren

Faculty of MedicineDepartment of Surgery & Cancer

Chair in Surgical Care Sciences
 
 
 
//

Contact

 

p.lagergren Website

 
 
//

Location

 

Block B Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Publication Type
Year
to

216 results found

Cheng Z, Johar A, Nilsson M, Schandl A, Lagergren Pet al., 2024, Cancer-related fatigue trajectories up to 5 years after curative treatment for oesophageal cancer., Br J Cancer, Vol: 130, Pages: 628-637

BACKGROUND: Whether cancer-related fatigue develops differently after curative-intended oesophageal cancer treatment and the related modifiable factors are unclear. METHODS: This population-based and longitudinal cohort included 409 oesophageal cancer patients who underwent curative oesophagectomy in 2013-2020 in Sweden. The main outcome was cancer-related fatigue trajectories with measurements at 1, 1.5, 2, 2.5, 3, 4 and 5 years postoperatively by validated EORTC QLQ-FA12 questionnaire, and analysed using growth mixture models. Weighted logistic regressions provided odds ratios (OR) with 95% confidence intervals (95% CI) for underlying sociodemographic, clinical, and patient-reported outcome factors in relation to the identified trajectories. RESULTS: Two distinct overall cancer-related fatigue trajectories were identified: low level of persistent fatigue and high level of increasing fatigue, with 64% and 36% of patients, respectively. The odds of having high level of fatigue trajectory were increased by Charlson comorbidity index (≥ 2 versus 0: OR = 2.52, 95% CI 1.07-5.94), pathological tumour Stage (III-IV versus 0-I: OR = 2.52, 95% CI 1.33-4.77), anxiety (OR = 7.58, 95% CI 2.20-26.17), depression (OR = 15.90, 95% CI 4.44-56.93) and pain (continuous score: OR = 1.02, 95% CI 1.01-1.04). CONCLUSIONS: Long-term trajectories with high level of increasing cancer-related fatigue and the associated modifiable factors were identified after oesophageal cancer treatment. The results may facilitate early identification and targeted intervention for such high-risk patients.

Journal article

Elliott JA, Klevebro F, Mantziari S, Markar SR, Goense L, Johar A, Lagergren P, Zaninotto G, van Hillegersberg R, van Berge Henegouwen MI, Schäfer M, Nilsson M, Hanna GB, Reynolds JV, ENSURE Study Groupet al., 2023, Neoadjuvant Chemoradiotherapy Versus Chemotherapy for the Treatment of Locally Advanced Esophageal Adenocarcinoma in the European Multicenter ENSURE Study., Ann Surg, Vol: 278, Pages: 692-700

OBJECTIVE: This study aimed to compare clinicopathologic, oncologic, and health-related quality of life (HRQL) outcomes following neoadjuvant chemoradiation (nCRT) and chemotherapy (nCT) in the ENSURE international multicenter study. BACKGROUND: nCT and nCRT are the standards of care for locally advanced esophageal cancer (LAEC) treated with curative intent. However, no published randomized controlled trial to date has demonstrated the superiority of either approach. METHODS: ENSURE is an international multicenter study of consecutive patients undergoing surgery for LAEC (2009-2015) across 20 high-volume centers (NCT03461341). The primary outcome measure was overall survival (OS), secondary outcomes included histopathologic response, recurrence pattern, oncologic outcome, and HRQL in survivorship. RESULTS: A total of 2211 patients were studied (48% nCT, 52% nCRT). pCR was observed in 4.9% and 14.7% ( P <0.001), with R0 in 78.2% and 94.2% ( P <0.001) post nCT and nCRT, respectively. Postoperative morbidity was equivalent, but in-hospital mortality was independently increased [hazard ratio (HR)=2.73, 95% CI: 1.43-5.21, P= 0.002] following nCRT versus nCT. Probability of local recurrence was reduced (odds ratio=0.71, 95% CI: 0.54-0.93, P =0.012), and distant recurrence-free survival time reduced (HR=1.18, 95% CI: 1.02-1.37, P =0.023) after nCRT versus nCT, with no difference in OS among all patients (HR=1.10, 95% CI: 0.98-1.25, P =0.113). On subgroup analysis, patients who underwent R0 resection following nCT as compared with nCRT had improved OS (median: 60.7 months, 95% CI: 49.5-71.8 vs 40.8 months, 95% CI: 42.8-53.4, P <0.001). CONCLUSIONS: In this European multicenter study, nCRT compared with nCT was associated with reduced probability of local recurrence but reduced distant recurrence-free survival for patients with LAEC, without differences in OS. These data support tailored patient-specific decision-making in the overall approach to achieving optimum o

Journal article

Edfeldt K, Hellman P, Granberg D, Lagergren P, Thiis-Evensen E, Sundin A, Andersson Cet al., 2023, Improved health-related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours, JOURNAL OF NEUROENDOCRINOLOGY, ISSN: 0953-8194

Journal article

van Leeuwen M, Kieffer JM, Young TE, Annunziata MA, Arndt V, Arraras JI, Autran D, Hani HB, Chakrabarti M, Chinot O, Cho J, da Costa Vieira RA, Darlington A-S, Debruyne PR, Dirven L, Doege D, Eller Y, Eichler M, Fridriksdottir N, Gioulbasanis I, Hammerlid E, van Hemelrijck M, Hermann S, Husson O, Jefford M, Johansen C, Kjaer TK, Kontogianni M, Lagergren P, Lidington E, Lisy K, Morag O, Nordin A, Al Omari ASH, Pace A, De Padova S, Petranovia D, Pinto M, Ramage J, Rammant E, Reijneveld J, Serpentini S, Sodergren S, Vassiliou V, Leeuw IV-D, Vistad I, Young T, Aaronson NK, van de Poll-Franse LV, EORTC QLGet al., 2023, Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire., J Cancer Surviv, Vol: 17, Pages: 1111-1130

PURPOSE: The purpose of this study is to develop a European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) questionnaire that captures the full range of physical, mental, and social health-related quality of life (HRQOL) issues relevant to disease-free cancer survivors. In this phase III study, we pretested the provisional core questionnaire (QLQ-SURV111) and aimed to identify essential and optional scales. METHODS: We pretested the QLQ-SURV111 in 492 cancer survivors from 17 countries with one of 11 cancer diagnoses. We applied the EORTC QLG decision rules and employed factor analysis and item response theory (IRT) analysis to assess and, where necessary, modify the hypothesized questionnaire scales. We calculated correlations between the survivorship scales and the QLQ-C30 summary score and carried out a Delphi survey among healthcare professionals, patient representatives, and cancer researchers to distinguish between essential and optional scales. RESULTS: Fifty-four percent of the sample was male, mean age was 60 years, and, on average, time since completion of treatment was 3.8 years. Eleven items were excluded, resulting in the QLQ-SURV100, with 12 functional and 9 symptom scales, a symptom checklist, 4 single items, and 10 conditional items. The essential survivorship scales consist of 73 items. CONCLUSIONS: The QLQ-SURV100 has been developed to assess comprehensively the HRQOL of disease-free cancer survivors. It includes essential and optional scales and will be validated further in an international phase IV study. IMPLICATIONS FOR CANCER SURVIVORS: The availability of this questionnaire will facilitate a standardized and robust assessment of the HRQOL of disease-free cancer survivors.

Journal article

Schandl A, Cheng Z, Johar A, Lagergren Pet al., 2023, Health-related quality of life 15 years after oesophageal cancer surgery: a prospective nationwide cohort study, JOURNAL OF CANCER SURVIVORSHIP, Vol: 17, Pages: 815-825, ISSN: 1932-2259

Journal article

Ringborg CH, Wengstrom Y, Schandl A, Lagergren Pet al., 2023, The long-term experience of being a family caregiver of patients surgically treated for oesophageal cancer, JOURNAL OF ADVANCED NURSING, Vol: 79, Pages: 2259-2268, ISSN: 0309-2402

Journal article

Elliott JR, Markar S, Klevebro F, Johar A, Goense L, Lagergren P, Zaninotto G, van Hillegersberg RI, Henegouwen MVB, Nilsson MB, Hanna GV, Reynolds Jet al., 2023, An International Multicenter Study Exploring Whether Surveillance After Esophageal Cancer Surgery Impacts Oncological and Quality of Life Outcomes (ENSURE), Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: E1035-E1044, ISSN: 0003-4932

Conference paper

Xie S-H, Santoni G, Bottai M, Gottlieb-Vedi E, Lagergren P, Lagergren Jet al., 2023, Prediction of conditional survival in esophageal cancer in a population-based cohort study, INTERNATIONAL JOURNAL OF SURGERY, Vol: 109, Pages: 1141-1148, ISSN: 1743-9191

Journal article

Schuring N, Markar SR, Hagens ERC, Jezerskyte E, Sprangers MAG, Lagergren P, Johar A, Gisbertz SS, Henegouwen MIVBet al., 2023, Health-related quality of life following neoadjuvant chemoradiotherapy versus perioperative chemotherapy and esophagectomy for esophageal cancer: a European multicenter study, DISEASES OF THE ESOPHAGUS, Vol: 36, ISSN: 1120-8694

Journal article

Gottlieb-Vedi E, Kauppila JH, Mattsson F, Hedberg J, Johansson J, Edholm D, Lagergren P, Nilsson M, Lagergren Jet al., 2023, Extent of Lymphadenectomy and Long-term Survival in Esophageal Cancer, ANNALS OF SURGERY, Vol: 277, Pages: 429-436, ISSN: 0003-4932

Journal article

Sjovall A, Lagergren P, Johar A, Buchli Cet al., 2023, Quality of life and patient reported symptoms after colorectal cancer in a Swedish population, COLORECTAL DISEASE, Vol: 25, Pages: 191-201, ISSN: 1462-8910

Journal article

Ringborg CH, Cheng Z, Johar A, Schandl A, Lagergren Pet al., 2023, Associations in health-related quality of life between patients and family caregivers 1 year after oesophageal cancer surgery, EUROPEAN JOURNAL OF ONCOLOGY NURSING, Vol: 62, ISSN: 1462-3889

Journal article

Schuring N, Jezerskyte E, Henegouwen MIVB, Sprangers MAG, Lagergren P, Johar A, Markar SR, Gisbertz SSet al., 2023, Influence of postoperative complications following esophagectomy for cancer on quality of life: A European multicenter study, EJSO, Vol: 49, Pages: 97-105, ISSN: 0748-7983

Journal article

Pieniowski EHA, Bergstroem CM, Nordenvall CAM, Westberg KS, Johar AM, Tumlin Ekelund SF, Larsson KR, Pekkari KJ, Jansson Palmer GC, Lagergren P, Abraham-Nordling Met al., 2023, A Randomized Controlled Clinical Trial of Transanal Irrigation Versus Conservative Treatment in Patients With Low Anterior Resection Syndrome After Rectal Cancer Surgery, ANNALS OF SURGERY, Vol: 277, Pages: 30-37, ISSN: 0003-4932

Journal article

Elliott JA, Markar SR, Hanna GB, Reynolds JV, Klevebro F, Johar A, Goense L, Lagergren P, Zaninotto G, van Hillegersberg R, Henegouwen MIB, Nilsson Met al., 2022, Surveillance, Oncologic Outcome and Health-Related Quality of Life: A Report from the ENSURE Study, Publisher: SPRINGER LONDON LTD, Pages: S225-S225, ISSN: 0021-1265

Conference paper

Gottlieb-Vedi E, Kauppila JHH, Mattsson F, Lindblad M, Nilsson M, Lagergren P, Rouvelas I, Lagergren J, FINEGO Get al., 2022, Long-term Survival in Esophageal Cancer After Minimally Invasive Esophagectomy Compared to Open Esophagectomy, ANNALS OF SURGERY, Vol: 276, Pages: E744-E748, ISSN: 0003-4932

Journal article

Pieniowski EHA, Nordenvall C, Johar A, Palmer G, Ekelund ST, Lagergren P, Abraham-Nordling Met al., 2022, Defunctioning stoma in rectal cancer surgery-A risk factor for Low Anterior Resection Syndrome?, EJSO, Vol: 48, Pages: 2518-2524, ISSN: 0748-7983

Journal article

Lundberg E, Lagergren P, Mattsson F, Lagergren Jet al., 2022, ASO Author Reflections: Decreased Life Expectancy in Esophageal Cancer Survivors, ANNALS OF SURGICAL ONCOLOGY, Vol: 29, Pages: 595-596, ISSN: 1068-9265

Journal article

Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski RT, Curigliano G, Felip E, Ferreira AR, Ganz PA, Hegarty J, Jeon J, Johansen C, Joly F, Jordan K, Koczwara B, Lagergren P, Lambertini M, Lenihan D, Linardou H, Loprinzi C, Partridge AH, Rauh S, Steindorf K, van der Graaf W, van de Poll-Franse L, Pentheroudakis G, Peters S, Pravettoni Get al., 2022, ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe, ANNALS OF ONCOLOGY, Vol: 33, Pages: 1119-1133, ISSN: 0923-7534

Journal article

Anandavadivelan P, Johar A, Lagergren P, 2022, The weight loss grading system as a predictor of cancer cachexia in oesophageal cancer survivors., QUALITY OF LIFE RESEARCH, Vol: 31, Pages: S38-S38, ISSN: 0962-9343

Journal article

Liu Y, Pettersson E, Schandl A, Markar S, Johar A, Lagergren Pet al., 2022, Dispositional optimism and all-cause mortality after esophageal cancer surgery: a nationwide population-based cohort study, SUPPORTIVE CARE IN CANCER, Vol: 30, Pages: 9461-9469, ISSN: 0941-4355

Journal article

Schandl A, Ringborg C, Malberg K, Johar A, Lagergren Pet al., 2022, Caregiver burden and health-related quality of life among family caregivers of oesophageal cancer patients: a prospective nationwide cohort study, ACTA ONCOLOGICA, Vol: 61, Pages: 1186-1191, ISSN: 0284-186X

Journal article

Kauppila JH, Rosenlund H, Klevebro F, Johar A, Anandavadivelan P, Malberg K, Lagergren Pet al., 2022, Minimally invasive surgical techniques for oesophageal cancer and nutritional recovery: a prospective population-based cohort study, BMJ OPEN, Vol: 12, ISSN: 2044-6055

Journal article

Anandavadivelan P, Malberg K, Vikstrom K, Nielsen S, Holdar U, Johar A, Lagergren Pet al., 2022, Home-based physical activity after treatment for esophageal cancer-A randomized controlled trial, CANCER MEDICINE, ISSN: 2045-7634

Journal article

Saggu R, Barlow P, Butler J, Ghaem-Maghami S, Hughes C, Lagergren P, McGregor A, Shaw C, Wells Met al., 2022, Considerations for mulitmodal prehabilitation in women with gynaecological cancers: a scoping review using realist principles, BMC Women's Health, Vol: 22, Pages: 1-35, ISSN: 1472-6874

Background: There is increasing recognition that prehabilitation is important as a means of preparing patients physically and psychologically for cancer treatment. However, little is understood about the role and optimal nature of prehabilitation for gynaecological cancer patients, who usually face extensive and life-changing surgery in addition to other treatments that impact significantly on physiological and psychosexual wellbeing. Review question: This scoping review was conducted to collate the research evidence on multimodal prehabilitation in gynaecological cancers and the related barriers and facilitators to engagement and delivery that should be considered when designing a prehabilitation intervention for this group of women. Methods: Seven medical databases and four grey literature repositories were searched from database inception to September 2021. All articles, reporting on multimodal prehabilitation in gynaecological cancers were included in the final review, whether qualitative, quantitative or mixed-methods. Qualitative on unimodal interventions were also included, as these were thought to be more likely to include information about barriers and facilitators which could also be relevant to multimodal interventions. A realist framework of context, mechanism and outcome was used to assist interpretation of findings. Results: In total, 24 studies were included in the final review. The studies included the following tumour groups: ovarian only (n=12), endometrial only (n=1), mixed ovarian, endometrial, vulvar (n=5) and non-specific gynaecological tumours (n=6). There was considerable variation across studies in terms of screening for prehabilitation, delivery of prehabilitation and outcome measures. Key mechanisms and contexts influencing engagement with prehabilitation can be summarised as: 1) The role of healthcare professionals and organisations 2) Patients’ perceptions of acceptability 3) Factors influencing patient motivation 4) Prehabilita

Journal article

Nilsson M, Olafsdottir H, Alexandersson von Doebeln G, Villegas F, Gagliardi G, Hellstroem M, Wang Q-L, Johansson H, Gebski V, Hedberg J, Klevebro F, Markar S, Smyth E, Lagergren P, Al-Haidari G, Rekstad LC, Aahlin EK, Wallner B, Edholm D, Johansson J, Szabo E, Reynolds JV, Pramesh CS, Mummudi N, Joshi A, Ferri L, Wong RKS, O'Callaghan C, Lukovic J, Chan KKW, Leong T, Barbour A, Smithers M, Li Y, Kang X, Kong F-M, Chao Y-K, Crosby T, Bruns C, van Laarhoven H, van Berge Henegouwen M, van Hillegersberg R, Rosati R, Piessen G, de Manzoni G, Lordick Fet al., 2022, Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial, FRONTIERS IN ONCOLOGY, Vol: 12, ISSN: 2234-943X

Journal article

Cheng Z, Anandavadivelan P, Nilsson M, Johar A, Lagergren Pet al., 2022, Body Mass Index-Adjusted Weight Loss Grading System and Cancer-Related Fatigue in Survivors 1 Year After Esophageal Cancer Surgery, ANNALS OF SURGICAL ONCOLOGY, Vol: 29, Pages: 4502-4510, ISSN: 1068-9265

Journal article

Kalager M, Adami H-O, Dickman PW, Lagergren P, Steindorf Ket al., 2022, Cancer outcome research - a European challenge Part II: Opportunities and priorities, MOLECULAR ONCOLOGY, Vol: 16, Pages: 2300-2311, ISSN: 1574-7891

Journal article

Lundberg E, Lagergren P, Mattsson F, Lagergren Jet al., 2022, Life Expectancy in Survivors of Esophageal Cancer Compared with the Background Population, ANNALS OF SURGICAL ONCOLOGY, Vol: 29, Pages: 2805-2811, ISSN: 1068-9265

Journal article

Cheng Z, Johar A, Nilsson M, Lagergren Pet al., 2022, Cancer-Related Fatigue After Esophageal Cancer Surgery: Impact of Postoperative Complications, ANNALS OF SURGICAL ONCOLOGY, Vol: 29, Pages: 2842-2851, ISSN: 1068-9265

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00986323&limit=30&person=true